Approved for use through 11/30/2005. OMB 0651-0035

Unknown

PB60663

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Examiner Name

Attorney Docket Number

Application Number To be Assigned **POWER OF ATTORNEY** 13 January 2005 Filing Date Baldwin, et al. First Named Inventor and **CORRESPONDENCE ADDRESS** INDOLE DERIVATIVES AND USE Title **INDICATION FORM** AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS **Art Unit** Unknown

I hereby appoint:		
E Practitioners associated with the Customer Numb	pers. 20462	
Or		
☐ Practitioner(s) named below:		
Name		Registration Number
As my/our attorney(s) or agent(s) to prosecute the applic	cation identified above	and to transact all business in the
United States Patent and Trademark Office connected the		and to transact an ousmess in the
Please recognize or change the correspondence address	for the above-identified	application to:
☐ The address associated with the above-mentioned C	ustomer Number:	
Or		
E The address associated with Customer Number 2	20462	
Or		
☐ Firm or Individual Name:		
Address:		
Address:		
City:	State:	Zip:
Country:		
Telephone:	Fax:	
I am the:		
☐ Applicant/Inventor:		
Application inventor. Assignee or record of the entire interest. See 3	7 CER 3 71	
Statement under 37 CFR 3.73(b) is enclosed. (
	E of Applicant or Assi	gnee of Record
Signature: Ver to	Date: July 12, 2006	
Name: Stephen Venetianer	Telephone: 610-270-	5040
Title and Company: Vice President, Pharmaceuticals, SmithKline Beecham Corporation		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.		
Submit multiple forms if more than one signature is required, see below*.		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CRF 3.73(b)			
Applicant/Patent Owner: SMITHKLINE BEECHAM CORPORATION			
Application No./Patent No.: TO BE ASSIGNED Filed/Issue Date: 13 January 2005			
Entitled: INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS			
IN PARTICULAR IKK2 INHIBITORS			
SMITHKLINE BEECHAM CORPORATION, a corporation, states that it is:			
1. Et the assignee of the entire right, title, and interest; or			
2. an assignee of less than the entire right, title and interest.			
The extent (by percentage) of its ownership interest is% in the patent application/patent identified above			
By virtue of either; A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was			
recorded in the United States Patent and Trademark Office at Reel, Frame, or for which			
copy thereof is attached.			
OR			
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee			
as shown below:			
1. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel, Frame, or for which a copy thereof is attached. 2. From: To:			
2. From: To: To: The document was recorded in the United States Patent and Trademark Office at			
The document was recorded in the United States Patent and Trademark Uffice at			
Reel, Frame, or for which a copy thereof is attached. 3. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel, Frame, or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supplemental sheet.			
[X] Copies of assignments or other documents in the chain of title are attached.			
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment			
Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.			
See MPEP 302.08]			
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.			
Signature Date			
STEPHEN VENETIANER610-270-5040			
Printed or Typed Name Telephone Number			
Vice President, Pharmaceuticals			
Title			
This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file			

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Assignment

WHEREAS, I/we Jeffrey K KERNS, a citizen of the United States of America and residing at King of Prussia, Pennsylvania, has/have invented or discovered certain improvements in "INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS" hereinafter referred to as said invention and improvements for which a priority application 0400895.9 was filed on 15 January 2004 in the United Kingdom and for which a PCT international application is now being filed designating the United States of America and naming assignor as inventor, and in the United States only applicant/inventor. I/We hereby authorize and request that the filing date and application number of said PCT application, when known be inserted in parentheses below.

(PCT/GB2005/000085 filed 13 January 2005)

WHEREAS, SMITHKLINE BEECHAM CORPORATION, a company incorporated in the State of Pennsylvania, USA, whose registered office is at One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101, USA, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, Jeffrey K KERNS for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said SMITHKLINE BEECHAM CORPORATION, throughout the United States of America, its territories and possessions, and in and to said application and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America;

AND, my/our whole right, title and interest in and to said invention and improvements to SMITHKLINE BEECHAM CORPORATION, in all other countries throughout the world, and in and to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

AND, I/we do hereby authorize and request the issue of any Letters Patent in the respective areas referred to, to said **SMITHKLINE BEECHAM CORPORATION**, as assignees of my/our whole right, title and interest in and to the same for the sole use and behoof of the said assignees, their successors and assigns as their interests appear herein;

AND, I/we warrant that I/we have not knowingly conveyed to others any right in said invention, improvements, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing said invention and improvements and that I/we have good right to assign the same to **SMITHKLINE BEECHAM CORPORATION**;

AND, I/we the undersigned Jeffrey K KERNS for the consideration aforesaid, do hereby agree that I/we or my/our executors or legal representatives, will provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, application papers, affidavits, assignments and other documents which may be necessary or desirable to more effectually secure to and vest in said SMITHKLINE BEECHAM CORPORATION, their successors and assigns, the whole right, title and interest in and to the said invention and improvements, applications, Letters Patent, rights, title and interest hereby sold, assigned and conveyed, or intended so to be. This assignment should be deemed effective as of 15 January 2004.

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

Inventor: Jeffrey K KERNS

Date